Portal de Periódicos da CAPES

Reactive Oxygen Intermediates Are Involved in the Induction of CD95 Ligand mRNA Expression by Cytostatic Drugs in Hepatoma Cells

1997; Elsevier BV; Volume: 272; Issue: 45 Linguagem: Inglês

10.1074/jbc.272.45.28191

1083-351X

Hubert Hug, Susanne Strand, Annette Grambihler, Jan Galle, Volker Hack, Wolfgang Stremmel, Peter H. Krammer, Peter R. Galle,

Synthesis and Characterization of Heterocyclic Compounds

Oxidative stress has been associated with the induction of programmed cell death. The CD95 ligand/receptor system is a specific mediator of apoptosis. We have used the model of drug-induced apoptosis to assess whether the CD95 ligand mRNA is induced by reactive oxygen intermediates. Treatment of HepG2 hepatoma cells with bleomycin induced the production of reactive oxygen intermediates and, as an additional parameter of oxidative stress, resulted in glutathione (GSH) depletion. In parallel, CD95 ligand mRNA expression was induced. In a similar fashion CD95 ligand mRNA expression increased after treatment with H2O2. Additional treatment with the antioxidant and GSH precursor N-acetylcysteine resulted in partial restoration of intracellular GSH levels and in reduced induction of CD95 ligand mRNA. Induction of CD95 ligand mRNA by bleomycin was further reduced by combined treatment withN-acetylcysteine and deferoxamine. These data suggest a direct role of oxygen radicals in the induction of the CD95 ligand. Oxidative stress has been associated with the induction of programmed cell death. The CD95 ligand/receptor system is a specific mediator of apoptosis. We have used the model of drug-induced apoptosis to assess whether the CD95 ligand mRNA is induced by reactive oxygen intermediates. Treatment of HepG2 hepatoma cells with bleomycin induced the production of reactive oxygen intermediates and, as an additional parameter of oxidative stress, resulted in glutathione (GSH) depletion. In parallel, CD95 ligand mRNA expression was induced. In a similar fashion CD95 ligand mRNA expression increased after treatment with H2O2. Additional treatment with the antioxidant and GSH precursor N-acetylcysteine resulted in partial restoration of intracellular GSH levels and in reduced induction of CD95 ligand mRNA. Induction of CD95 ligand mRNA by bleomycin was further reduced by combined treatment withN-acetylcysteine and deferoxamine. These data suggest a direct role of oxygen radicals in the induction of the CD95 ligand. CD95 (APO-1/Fas) is a 45-kDa glycosylated transmembrane protein belonging to the tumor necrosis factor receptor family of type I membrane proteins (1Nagata S. Golstein P. Science. 1995; 267: 1449-1456Crossref PubMed Scopus (3972) Google Scholar, 2Nagata S. Cell. 1997; 88: 355-365Abstract Full Text Full Text PDF PubMed Scopus (4543) Google Scholar). The CD95 ligand (CD95L) is a 40-kDa Type II transmembrane protein and a member of the tumor necrosis factor family of cytokines (1Nagata S. Golstein P. Science. 1995; 267: 1449-1456Crossref PubMed Scopus (3972) Google Scholar, 3Suda T. Okazaki T. Naito Y. Yokota N. Arai S. Ozaki K. Nakao K. Nagata S. J. Immunol. 1995; 154: 3806-3813PubMed Google Scholar). In addition to the transmembrane form, a soluble form of the CD95L exists (4Mariani S.M. Matiba B. Bäumler C. Krammer P.H. Eur. J. Immunol. 1995; 25: 2303-2307Crossref PubMed Scopus (213) Google Scholar). Binding of the CD95L to its receptor CD95 induces apoptosis. The CD95/CD95L system plays a role in the deletion of T lymphocytes in the peripheral immune system, in the shutting off of an immune response, in T lymphocyte-mediated cytotoxicity, and in the elimination of CD95-expressing leukocytes in immune privileged sites (5Dhein J. Walczak H. Bäumler C. Debatin K.-M. Krammer P.H. Nature. 1995; 373: 438-441Crossref PubMed Scopus (1606) Google Scholar, 6Strasser A. Nature. 1995; 373: 385-386Crossref PubMed Scopus (71) Google Scholar, 7Abbas A.K. Cell. 1996; 84: 655-657Abstract Full Text Full Text PDF PubMed Scopus (228) Google Scholar, 8Lau H.T. Yu M. Fontana A. Stoeckert Jr., C.J. Science. 1996; 273: 109-112Crossref PubMed Scopus (424) Google Scholar, 9Matiba B. Mariani S.M. Krammer P.H. Semin. Immunol. 1997; 9: 59-68Crossref PubMed Scopus (64) Google Scholar, 10Strand S. Hofmann W.J. Hug H. Müller M. Otto G. Strand D. Stremmel W. Krammer P.H. Galle P.R. Nat. Med. 1996; 2: 1361-1367Crossref PubMed Scopus (879) Google Scholar). CD95 signaling occurs through the death-inducing signaling complex and the activation of a cascade of interleukin converting enzyme/Ced3 proteases (11Fraser A. Evan G. Cell. 1996; 85: 781-784Abstract Full Text Full Text PDF PubMed Scopus (612) Google Scholar, 12Medema J.P. Scaffidi C. Kischkel F.C. Shevchenko A. Mann M. Krammer P.H. Peter M.E. EMBO J. 1997; 16: 2794-2804Crossref PubMed Scopus (1039) Google Scholar), which are now designated caspases (13Alnemri E.S. Livingston D.L. Nicholson D.W. Salvesen G. Thornberry N.A. Wong W.W. Yuan J. Cell. 1996; 87: 171Abstract Full Text Full Text PDF PubMed Scopus (2133) Google Scholar). A cell expressing both CD95 and CD95L undergoes suicide or can cause fratricide (5Dhein J. Walczak H. Bäumler C. Debatin K.-M. Krammer P.H. Nature. 1995; 373: 438-441Crossref PubMed Scopus (1606) Google Scholar, 6Strasser A. Nature. 1995; 373: 385-386Crossref PubMed Scopus (71) Google Scholar). CD95L is expressed in activated T lymphocytes (3Suda T. Okazaki T. Naito Y. Yokota N. Arai S. Ozaki K. Nakao K. Nagata S. J. Immunol. 1995; 154: 3806-3813PubMed Google Scholar) but its expression can also be induced by cytostatic agents in a variety of different cell lines (14Friesen C. Herr I. Krammer P.H. Debatin K.-M. Nat. Med. 1996; 2: 574-577Crossref PubMed Scopus (951) Google Scholar, 15Müller M. Strand S. Hug H. Heinemann E.-A. Walczak H. Hofmann W.J. Stremmel W. Krammer P.H. Galle P. J. Clin. Invest. 1997; 99: 403-413Crossref PubMed Scopus (716) Google Scholar). Furthermore, CD95L expression has been observed in hepatocytes in vivo in patients with alcoholic hepatitis (16Galle P.R. Hofmann W.J. Walczak H. Schaller H. Otto G. Stremmel W. Krammer P.H. Runkel L. J. Exp. Med. 1995; 182: 1223-1230Crossref PubMed Scopus (676) Google Scholar). Thus, CD95L expression seems to be induced by different mechanisms of cellular injury and might be an important tool for the organism to eliminate damaged cells. Little is known about the exact mechanism of induction of CD95L. The CD95L promoter has been described to contain NF-κB binding sites (17Takahashi T. Tanaka M. Inazawa J. Abe T. Suda T. Nagata S. Int. Immunol. 1994; 6: 1567-1574Crossref PubMed Scopus (416) Google Scholar). Therefore, induction of CD95L mRNA might involve reactive oxygen species (ROS). 1The abbreviations used are: ROS, reactive oxygen species; RT-PCR, reverse transcription-polymerase chain reaction; PBS, phosphate-buffered saline. 1The abbreviations used are: ROS, reactive oxygen species; RT-PCR, reverse transcription-polymerase chain reaction; PBS, phosphate-buffered saline. In line with this assumption is the observation of apoptotic cell death in different cell lines after oxidative stress (18Jacobson M.D. Trends Biochem. Sci. 1996; 21: 83-86Abstract Full Text PDF PubMed Scopus (728) Google Scholar, 19Kroemer G. Zamzami N. Susin S.A. Immunol. Today. 1997; 18: 44-51Abstract Full Text PDF PubMed Scopus (1382) Google Scholar). In the present study we have used the model of bleomycin-induced apoptosis to investigate the possible role of ROS in the induction of CD95L mRNA. Bleomycin has been described as a potent inducer of apoptosis, involving up-regulation of CD95 receptor and ligand expression (15Müller M. Strand S. Hug H. Heinemann E.-A. Walczak H. Hofmann W.J. Stremmel W. Krammer P.H. Galle P. J. Clin. Invest. 1997; 99: 403-413Crossref PubMed Scopus (716) Google Scholar). Whereas up-regulation of the CD95 receptor in response to cell damage apparently involves activity of the p53 tumor suppressor gene product, the mechanism of CD95L induction is unclear to date. Because bleomycin treatment induces oxidative stress (20Kilinc C. Ozcan O. Karaoz E. Sunguroglu K. Kutluay T. Karaca L. J. Basic Clin. Physiol. Pharmacol. 1993; 4: 249-269Crossref PubMed Scopus (35) Google Scholar, 21An J. Hsie A.W. Mutat. Res. 1992; 270: 167-175Crossref PubMed Scopus (25) Google Scholar, 22An J. Hsie A.W. Mutat. Res. 1993; 289: 215-222Crossref PubMed Scopus (26) Google Scholar) it provides a suitable model for the investigation of the potential association between induction of ROS and CD95L. In this study we demonstrate that CD95L mRNA induction indeed involves the action of ROS which can be blocked by the antioxidants N-acetylcysteine and deferoxamine. HepG2 cells, a human hepatoblastoma cell line, were cultured in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine serum. Bleomycin (Cell Pharm, Hannover, Germany) was used at 3 mg/ml. N-Acetylcysteine (Sigma) was used at 50 μm, deferoxamine (desferrioxamine mesylate; Sigma, Deisenhofen, Germany) at 50 mm. At these concentrations N-acetylcysteine and deferoxamine proved to be nontoxic for HepG2 cells as demonstrated by viability assays, lactate dehydrogenase release, and morphological analysis (data not shown). Poly(A)+-RNA was purified from about 5 × 105 HepG2 cells treated with bleomycin using the Oligotex Direct mRNA kit (Qiagen, Hilden, Germany) according to the protocol of the manufacturer. RNA was eluted with 50 μl of H2O. RT-PCR was performed using the Gen-Amp RNA-PCR kit from Perkin-Elmer. Reverse transcription was done with oligo(dT)16 and 3 μl of the poly(A)+-RNA under the conditions recommended by the manufacturer. The primers used for amplification of the CD95L mRNA have been described recently (23Peter M.E. Dhein J. Ehret A. Hellbardt S. Walczak H. Moldenhauer G. Krammer P.H. Int. Immunol. 1995; 7: 1873-1877Crossref PubMed Scopus (57) Google Scholar) and were used at a final concentration of 0.2 μm. Human β-actin primers were from Stratagene (Catalog No. 302010) and used at a final concentration of 0.1 μm. 35 PCR cycles were performed at 94 °C for 30 s, at 56 °C for 30 s, and at 72 °C for 2 min in a volume of 100 μl. 10 μl of the PCR sample were analyzed on 1.5% agarose gels. In all cases at least three independent sets of experiments were performed. Floating cells from the tissue culture supernatant were collected by centrifugation at 200 ×g. Adherent cells were harvested by incubation with 1% trypsin. HepG2 cells were collected by centrifugation at 200 ×g, washed with PBS, and fixed in 70% ethanol. This was followed by staining with propidium iodide (50 μg/ml PBS). DNA fluorescence was measured in a Becton Dickinson FACScan according to the method of Nicoletti et al. (24Nicoletti I. Migliorati G. Paggliacci M.C. Grignani F. Riccardi C.A J. Immunol. Methods. 1991; 139: 271-279Crossref PubMed Scopus (4415) Google Scholar). A minimum of 10,000 events was measured per sample. Data analysis was performed with Lysis II software. HepG2 cells were maintained on 35-mm plates. After bleomycin treatment cells were harvested with a cell scraper, washed in PBS, and finally taken up in 300 μl of 2.5% trichloroacetic acid and analyzed for intracellular glutathione and glutathione disulfide as described (25Eck H.-P. Gmünder H. Hartmann M. Petzhold D. Biol. Chem. Hoppe-Seyler. 1989; 370: 101-108Crossref PubMed Scopus (315) Google Scholar). O·̄2 generation was detected by a chemiluminescence reaction as described previously (26Galle J. Bengen J. Schollmeyer P. Wanner C. Circulation. 1995; 92: 1582-1589Crossref PubMed Scopus (131) Google Scholar). HepG2 cells were subconfluently seeded in sterile scintillation vials and treated with 3 mg/ml bleomycin for 24 h. Thereafter, medium was discarded and replaced by the scintillation solution containing 0.25 mmol/L lucigenin (Sigma) dissolved in 2 ml of Krebs-HEPES buffer. Counts were obtained at 1-min intervals at room temperature. To determine the specificity of the reaction the O·̄2 scavenger 4,5-dihydroxy-1,3-benzene disulfonic acid (Tiron, 10 mmol/L, Sigma) was added. Treatment with bleomycin in concentrations between 10 μg/ml and 3 mg/ml induces apoptosis as demonstrated by the appearance of a sub-G1 fraction of fragmented nuclei using propidium iodide staining and FACS analysis according to Nicolettiet al. (24Nicoletti I. Migliorati G. Paggliacci M.C. Grignani F. Riccardi C.A J. Immunol. Methods. 1991; 139: 271-279Crossref PubMed Scopus (4415) Google Scholar) (Fig.1 A; see also Ref. 15Müller M. Strand S. Hug H. Heinemann E.-A. Walczak H. Hofmann W.J. Stremmel W. Krammer P.H. Galle P. J. Clin. Invest. 1997; 99: 403-413Crossref PubMed Scopus (716) Google Scholar) and by morphological and DNA fragmentation analysis (data not shown). This is accompanied by an induction of CD95 mRNA (15Müller M. Strand S. Hug H. Heinemann E.-A. Walczak H. Hofmann W.J. Stremmel W. Krammer P.H. Galle P. J. Clin. Invest. 1997; 99: 403-413Crossref PubMed Scopus (716) Google Scholar) and also of CD95L mRNA (Fig. 1 B). The functional relevance of this observation has been demonstrated by blocking access of CD95L to the CD95 receptor using F(ab′)2 antagonistic antibody fragments which largely inhibited induction of apoptosis (15Müller M. Strand S. Hug H. Heinemann E.-A. Walczak H. Hofmann W.J. Stremmel W. Krammer P.H. Galle P. J. Clin. Invest. 1997; 99: 403-413Crossref PubMed Scopus (716) Google Scholar). Here, HepG2 cells were treated with 3 mg/ml bleomycin for 0, 5, 10, 24, 32, and 48 h, and expression of CD95L mRNA was assessed by RT-PCR. CD95L mRNA expression was detectable after 5 h, showed its highest level between 24 and 32 h, and decreased around 48 h (Fig.1 B). Recently we demonstrated dependence of CD95 induction on the presence of the tumor suppressor gene product p53 (15Müller M. Strand S. Hug H. Heinemann E.-A. Walczak H. Hofmann W.J. Stremmel W. Krammer P.H. Galle P. J. Clin. Invest. 1997; 99: 403-413Crossref PubMed Scopus (716) Google Scholar). CD95 expression took place only in hepatoma cell lines with p53 wild type configuration (HepG2) but not with p53 mutant configuration (Huh7) or in the absence of p53 (Hep3b). In contrast, CD95L mRNA was found to be inducible independently of the presence of p53 wild type and thus, seems to be regulated in a different manner (15Müller M. Strand S. Hug H. Heinemann E.-A. Walczak H. Hofmann W.J. Stremmel W. Krammer P.H. Galle P. J. Clin. Invest. 1997; 99: 403-413Crossref PubMed Scopus (716) Google Scholar). Since bleomycin treatment has been described to result in oxidative stress (21An J. Hsie A.W. Mutat. Res. 1992; 270: 167-175Crossref PubMed Scopus (25) Google Scholar, 22An J. Hsie A.W. Mutat. Res. 1993; 289: 215-222Crossref PubMed Scopus (26) Google Scholar), we posed the question whether CD95L mRNA activation is correlated to the generation of ROS in response to bleomycin treatment. In initial experiments we investigated the induction of oxidative stress following bleomycin treatment in hepatoma cells. As a parameter of oxidative stress intracellular glutathione (GSH) levels were assessed. Bleomycin treatment resulted in a rapid depletion of total GSH from initial values of 18 nmol/mg of protein in untreated controls to 0.7 nmol/mg of protein after 48 h (Fig.2 A) indicating disturbances in the cellular redox status. Additional treatment withN-acetylcysteine partially prevented GSH depletion of bleomycin-treated cells, with GSH levels of 14.8 nmol/mg of protein after 48 h. As a direct measure of induction of reactive oxygen species in bleomycin-treated cells we investigated generation of superoxide (O·̄2) using a chemiluminescence assay (26Galle J. Bengen J. Schollmeyer P. Wanner C. Circulation. 1995; 92: 1582-1589Crossref PubMed Scopus (131) Google Scholar). We observed a strong induction in chemiluminescence following treatment with 3 mg/ml bleomycin for 24 h. This signal could be completely blunted by addition of the O·̄2 scavenger Tiron, demonstrating specificity of the reaction. To establish a causative relationship between the observed induction of CD95L mRNA and presence of reactive oxygen species we treated HepG2 cells with H2O2. In a manner similar to bleomycin treatment H2O2 at concentrations between 0.1 and 10 μm induced expression of CD95L mRNA (Fig.3 A). Higher concentrations proved to be cytotoxic as demonstrated by a decrease in cell number and a consecutive decrease in β-actin and CD95L mRNA expression (data not shown). Further evidence for ROS-mediated CD95L mRNA expression was obtained from experiments with the antioxidants deferoxamine andN-acetylcysteine. Deferoxamine is an iron chelator. It prevents the formation of the hydroxyl radical from hydrogen peroxide via the Fenton reaction (27Yu B.P. Physiol. Rev. 1994; 74: 139-162Crossref PubMed Scopus (2202) Google Scholar).N-Acetylcysteine interferes with the generation of ROS and is a glutathione precursor. A direct effect of glutathione depletion on the induction of apoptosis seems unlikely, because glutathione depletion alone (using buthionine sulfoximine treatment of human leukocytes) failed to induce apoptosis (28Sato N. Iwata S. Nakamura K. Hori T. Mori K. Yodoi J. J. Immunol. 1995; 154: 3194-3203PubMed Google Scholar). HepG2 cells were treated with bleomycin (3 mg/ml) for up to 48 h in the absence or presence of antioxidants as shown in Fig. 3 B. At ∼32 h maximum expression of CD95L mRNA was reached. This expression was reduced in the presence of N-acetylcysteine. A further reduction to almost undetectable levels is observed in the presence ofN-acetylcysteine and deferoxamine (Fig. 3 B,lower panel). Deferoxamine alone did not result in a reproducible decrease of CD95L mRNA expression (data not shown). In a similar fashion, H2O2-induced CD95L expression was reduced in the presence of N-acetylcysteine and deferoxamine (data not shown). Taken together the above data point to an important role of ROS in the transcriptional regulation of CD95L expression. Interestingly and in agreement with our experimental evidence in hepatoma cells, a positive correlation between the intracellular levels of ROS and CD95L expression has been observed recently in activation-induced death of mature T lymphocytes and hybridomas (29Williams M.S. Henkart P.A. J. Immunol. 1996; 157: 2395-2402PubMed Google Scholar). The exact mechanism of CD95L mRNA induction via ROS remains to be clarified. Potentially involved regulatory proteins include redox-dependent transcription factors such as NF-κB or AP-1. Our data suggest a coordinated activation of the CD95 system in induction of apoptosis and thus elimination of injured cells, which involves p53-mediated expression of the CD95 receptor in response to DNA damage and ROS-mediated expression of the CD95 ligand. This might result in autocrine suicide of damaged cells and might add to the concept of maintenance of genomic integrity as it has been suggested as an important functional role of p53. Any alteration of the cellular capability to respond to cytostatic agents both on the level of CD95 or CD95L might result in a decreased sensitivity toward chemotherapeutic drug action and could thus add to primary or secondary resistance to anti-cancer therapy. The expert technical assistance of Martina Seyferth is gratefully acknowledged. We are indebted to Heinz Schaller for generous support.